Determination of Fibrinogen and Fibrinogenolytic Activity

SummaryA method for determining plasma fibrinogen and fibrinogenolytic activity, with epsilonaminocaproic acid (ε-ACA) as an inhibitor of fibrinolysis, in patients with high fibrinolytic activity, is described in detail.The fibrinogen was determined by a modification of Morrison’s syneresis method in parallel in 1. citrated plasma that was incubated for 2 hours at 37° C, after which further digestion was prevented by addition of ε-ACA and is referred to as fibrinogen A, and 2. in citrated plasma prepared from blood collected in tubes containing ε-ACA to prevent activation of plasminogen and is referred to as fibrinogen B. The difference between fibrinogen B and fibrinogen A gives the amount of lysed fibrinogen in 2 hours at 37° C. Fibrinogen B gives the fibrinogen concentration at the moment of sampling.The method is recommended to be used for evaluation of the true plasma fibrinogen level and the degree of fibrinogenolytic activity. This is particularly important during thrombolytic therapy.

Download Full-text

Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

Thrombosis and Haemostasis ◽

10.1055/s-0038-1649476 ◽

1993 ◽

Vol 70 (02) ◽

pp. 241-243 ◽

Cited By ~ 79

Author(s):

Adriana Branchi ◽

Angelo Rovellini ◽

Domenico Sommariva ◽

Angelo G Gugliandolo ◽

Angelo Fasoli

Keyword(s):

Slow Release ◽

Fibrinogen Level ◽

Plasma Fibrinogen ◽

Fibrinogen Concentration ◽

Plasma Fibrinogen Level ◽

Primary Hypercholesterolemia ◽

Reductase Inhibitors ◽

Hmg Coa Reductase Inhibitors ◽

Coa Reductase ◽

Hypocholesterolemic Drugs

SummaryIn order to evaluate the effects of hypocholesterolemic drugs on plasma fibrinogen concentration, six groups of subjects with primary hypercholesterolemia have been put on treatment with diet alone or diet plus fenofibrate (100 mg t.i.d.), slow release bezafibrate (400 mg once a day), gemfibrozil (600 mg b.i.d.), simvastatin (20 mg once a day) or pravastatin (20 mg once a day) respectively. After 1 month of therapy, plasma fibrinogen significantly decreased by 9% and 15% in fenofibrate and bezafibrate groups respectively and increased by 19% in gemfibrozil treated patients. After 4 months of therapy the changes were −16% with fenofibrate, −10% with bezafibrate and +20% with gemfibrozil. No significant changes were observed in patients treated with diet alone, simvastatin or pravastatin. The fibrinogen lowering effect of fenofibrate and bezafibrate does not seem to be related to the hypolipidemic activity of the drugs.

Download Full-text

The Relationship of Plasma Fibrinogen, Erythrocyte Flexibility and Blood Viscosity

Thrombosis and Haemostasis ◽

10.1055/s-0038-1651881 ◽

1977 ◽

Vol 38 (03) ◽

pp. 0660-0667 ◽

Cited By ~ 18

Author(s):

P. A Dupont ◽

J. A Sirs

Keyword(s):

Blood Viscosity ◽

Fibrinogen Level ◽

Plasma Viscosity ◽

Plasma Fibrinogen ◽

Fibrinogen Concentration ◽

Plasma Fibrinogen Level ◽

Shear Rates ◽

High Shear Rates ◽

Direct Measurements ◽

Relationship Of

SummaryMeasurements have been made of plasma fibrinogen concentration, erythrocyte flexibility and blood viscosity at shear rates from 5.75 to 230 sec−1 during and following surgery. In the post-operative period the plasma fibrinogen level in the patient rose to over 1,000 mg/dl and because there were subsequent complications, only returned to normal after 4 weeks. There was an associated change of erythrocyte flexibility, with a correlation coefficient of 0.98. The blood viscosity also varied with the plasma fibrinogen level, the effect being more pronounced at low shear rates. The internal viscosity of the red blood cell, calculated from the plasma viscosity and whole blood viscosity at 230 sec−1, decreases with increasing plasma fibrinogen concentration, in agreement with the direct measurements made of erythrocyte flexibility. It is proposed that at high shear rates an increase in plasma viscosity due to an elevation of fibrinogen concentration, is offset by a decrease in the rigidity of the erythrocytes, and these 2 effects counter-balance.

Download Full-text

Oral contraceptives and oestrogen replacement therapy as determinants of plasma fibrinogen level and fibrinolytic activity the northern sweden MONICA study

Fibrinolysis and Proteolysis ◽

10.1016/s0268-9499(98)80389-5 ◽

1998 ◽

Vol 12 (6) ◽

pp. 328-334 ◽

Cited By ~ 3

Author(s):

V. Lundberg ◽

K. Asplund ◽

P.-E. Evrin ◽

M. Eliasson

Keyword(s):

Replacement Therapy ◽

Oral Contraceptives ◽

Fibrinolytic Activity ◽

Fibrinogen Level ◽

Plasma Fibrinogen ◽

Plasma Fibrinogen Level ◽

Northern Sweden ◽

Oestrogen Replacement Therapy

Download Full-text

Platelet Adhesiveness and Fibrinolysis after Recent Cerebro-Vascular Accidents and their Relationship with Subsequent Deep Venous Thrombosis of the Legs

Thrombosis and Haemostasis ◽

10.1055/s-0038-1648016 ◽

1976 ◽

Vol 36 (01) ◽

pp. 127-132 ◽

Cited By ~ 11

Author(s):

C. P Warlow ◽

J. A. N Rennie ◽

D Ogston ◽

A. S Douglas

Keyword(s):

Platelet Count ◽

Venous Thrombosis ◽

Deep Venous Thrombosis ◽

Plasminogen Activator ◽

Fibrinogen Level ◽

Plasma Fibrinogen ◽

Platelet Adhesiveness ◽

Plasma Fibrinogen Level ◽

Vascular Accidents ◽

Subsequent Rise

SummaryIn fifteen patients with a cerebro-vascular accident resulting in an acute hemiplegia there was a subsequent rise in the platelet count and plasma fibrinogen level. There were no significant alterations in platelet adhesiveness, plasminogen activator, plasminogen, FR-antigen and haematocrit. Patients diagnosed as developing deep venous thrombosis with the 125I-fibrinogen technique had a significantly lower platelet adhesiveness and plasminogen level than those who were not.

Download Full-text

Variation in the Promoter Region of the β Fibrinogen Gene Is Associated with Plasma Fibrinogen Levels in Smokers and Non-Smokers

Thrombosis and Haemostasis ◽

10.1055/s-0038-1648177 ◽

1991 ◽

Vol 65 (05) ◽

pp. 487-490 ◽

Cited By ~ 115

Author(s):

A E Thomas ◽

F R Green ◽

C H Kelleher ◽

H C Wilkes ◽

P J Brennan ◽

...

Keyword(s):

Heart Disease ◽

Promoter Region ◽

Fragment Length Polymorphism ◽

Fibrinogen Level ◽

Plasma Fibrinogen ◽

Plasma Fibrinogen Level ◽

Healthy Men ◽

History Of ◽

General Practices ◽

Restriction Fragment Length

SummaryWe investigated the association between fibrinogen levels and a HaeIII restriction fragment length polymorphism located at −453 bp from the start of transcription of the β fibrinogen gene. 292 healthy men aged 45 to 69 years, recruited from general practices throughout Britain, were studied. None had a history of ischaemic heart disease. 41.1% (120) were smokers and fibrinogen levels were higher in this group. The frequency of the noncutting allele (designated H2) was 0.19 and was the same in smokers and non-smokers. The H2 allele was associated with elevated levels of fibrinogen in both smokers and non-smokers and the effect of genotype was similar in both groups. After smoking, HaeIII genotype was the strongest predictor of fibrinogen levels and explained 3.1% of the variance in fibrinogen levels. These results confirm earlier studies that variation at the fibrinogen locus contributes to the between-individual differences in plasma fibrinogen level.

Download Full-text

A Six Year Prospective Study of Fibrinogen and Other Risk Factors Associated with Mortality in Stable Claudicants

Thrombosis and Haemostasis ◽

10.1055/s-0038-1656361 ◽

1992 ◽

Vol 68 (03) ◽

pp. 261-263 ◽

Cited By ~ 71

Author(s):

A K Banerjee ◽

J Pearson ◽

E L Gilliland ◽

D Goss ◽

J D Lewis ◽

...

Keyword(s):

Risk Factors ◽

Intermittent Claudication ◽

Fibrinogen Level ◽

Past History ◽

Fold Increase ◽

Arterial Disease ◽

Plasma Fibrinogen ◽

Plasma Fibrinogen Level ◽

Factors Associated ◽

Probability Of Death

SummaryA total of 333 patients with stable intermittent claudication at recruitment were followed up for 6 years to determine risk factors associated with subsequent mortality. Cardiovascular diseases were the underlying cause of death in 78% of the 114 patients who died. The strongest independent predictor of death during the follow-up period was the plasma fibrinogen level, an increase of 1 g/l being associated with a nearly two-fold increase in the probability of death within the next 6 years. Age, low ankle/brachial pressure index and a past history of myocardial infarction also increased the probability of death during the study period. The plasma fibrinogen level is a valuable index of those patients with stable intermittent claudication at high risk of early mortality. The results also provide further evidence for the involvement of fibrinogen in the pathogenesis of arterial disease.

Download Full-text